20 Result(s)

Article

Enhancing pediatric access to cell and gene therapies

Increasing numbers of cell and gene therapies (CGTs) are emerging to treat and cure pediatric diseases. However, small market sizes limit the potential return on investment within the traditional biopharmaceut...

Crystal L. Mackall, Catherine M. Bollard, Nancy Goodman, Casey Carr… in Nature Medicine (2024)

Article

Unanswered questions following reports of secondary malignancies after CAR-T cell therapy

Reports of T cell malignancies after CAR-T cell therapy should be investigated, but existing data from follow-up studies suggest a low risk compared with other cancer treatments.

Bruce L. Levine, Marcelo C. Pasquini, John E. Connolly, David L. Porter… in Nature Medicine (2024)

Article

Tumor inflammation-associated neurotoxicity

Cancer immunotherapies have unique toxicities. Establishment of grading scales and standardized grade-based treatment algorithms for toxicity syndromes can improve the safety of these treatments, as observed f...

Jasia Mahdi, Jorg Dietrich, Karin Straathof, Claire Roddie… in Nature Medicine (2023)

Article

Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication

The disialoganglioside GD2 is overexpressed on several solid tumors, and monoclonal antibodies targeting GD2 have substantially improved outcomes for children with high-risk neuroblastoma. However, approximate...

Johanna Theruvath, Marie Menard, Benjamin A. H. Smith, Miles H. Linde… in Nature Medicine (2022)

Article

Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid/rhabdoid tumors

Atypical teratoid/rhabdoid tumors (ATRTs) typically arise in the central nervous system (CNS) of children under 3 years of age. Despite intensive multimodal therapy (surgery, chemotherapy and, if age permits, ...

Johanna Theruvath, Elena Sotillo, Christopher W. Mount… in Nature Medicine (2020)

Article

Clinical lessons learned from the first leg of the CAR T cell journey

Chimeric antigen receptor (CAR) T cell therapy for B cell malignancies has surpassed expectations, driving an ever-expanding number of clinical trials and the first US Food and Drug Administration approvals of...

Robbie G. Majzner, Crystal L. Mackall in Nature Medicine (2019)

Article

CAR T cell therapy: inroads to response and resistance

Here, we highlight key papers published in 2018 that advance our understanding of resistance to chimeric antigen receptor (CAR) T cell immunotherapy for leukaemia and lymphoma and in so doing reveal barriers t...

Christine E. Brown, Crystal L. Mackall in Nature Reviews Immunology (2019)

Article

Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M⁺ diffuse midline gliomas

Diffuse intrinsic pontine glioma (DIPG) and other diffuse midline gliomas (DMGs) with mutated histone H3 K27M (H3-K27M)^1–5 are aggressive and universally fatal pediatric brain cancers⁶. Chimeric antigen receptor ...

Christopher W. Mount, Robbie G. Majzner, Shree Sundaresh, Evan P. Arnold… in Nature Medicine (2018)

Article

CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy

Fry et al. report the first results from a human trial of a CD22-directed chimeric antigen receptor (CAR) T cell therapy providing evidence of efficacy in the treatment of pre–B cell acute lymphoblastic leukemia ...

Terry J Fry, Nirali N Shah, Rimas J Orentas, Maryalice Stetler-Stevenson… in Nature Medicine (2018)

Article

4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors

Crystal Mackall and colleagues report that antigen-independent signaling of chimeric antigen receptors (CARs) causes T cell exhaustion and reduced therapeutic efficacy of CAR T cells that can be overcome by in...

Adrienne H Long, Waleed M Haso, Jack F Shern, Kelsey M Wanhainen… in Nature Medicine (2015)

Article

Harnessing the biology of IL-7 for therapeutic application

Article

Interleukin 7 signaling in dendritic cells regulates the homeostatic proliferation and niche size of CD4⁺ T cells

Compared with naive CD8+ T cells, naive CD4⁺ T cells undergo inefficient homeostatic proliferation. Mackall and colleagues now attribute this difference to interleukin 7–mediated suppression of the expression of ...

Martin Guimond, Rachelle G Veenstra, David J Grindler, Hua Zhang… in Nature Immunology (2009)

Article

Lymphopenia and interleukin-2 therapy alter homeostasis of CD4⁺CD25⁺ regulatory T cells

CD4⁺CD25⁺ regulatory T (T_reg) cells have a crucial role in maintaining immune tolerance. Mice and humans born lacking T_reg cells develop severe autoimmune disease^1,2, and depletion of T_reg cells in lymphopenic mi...

Hua Zhang, Kevin S Chua, Martin Guimond, Veena Kapoor, Margaret V Brown… in Nature Medicine (2005)